Industry experts helped Barrons.com find five drug candidates that could receive Food and Drug Administration approval in 2011 and advance the treatment of a serious illness. To make the list, a drug must also deliver blockbuster sales.
The list includes the lupus drug Benlysta from Human Genome Sciences (NASDAQ: HGSI - News) and GlaxoSmithKline (NYSE: GSK - News), and skin-cancer drug ipilimumab from Bristol-Myers Squibb (NYSE: BMY - News).
Vertex Pharmaceuticals (NASDAQ: VRTX - News) and Johnson & Johnson (NYSE: JNJ - News) have telaprevir for hepatitis C, while Incyte (NASDAQ: INCY - News) and Novartis (NYSE: NVS - News) are developing a drug currently known as "INCB18424" for blood cancer.
Drugs generally don't develop more market-friendly names until closer to FDA approval.
Meanwhile, J&J and Bayer's (NYSE: BYR.L - News) long-overdue blood thinner Xarelto could finally get launched this year.
Sorry, Lilly is not on the list.
The list includes the lupus drug Benlysta from Human Genome Sciences (NASDAQ: HGSI - News) and GlaxoSmithKline (NYSE: GSK - News), and skin-cancer drug ipilimumab from Bristol-Myers Squibb (NYSE: BMY - News).
Vertex Pharmaceuticals (NASDAQ: VRTX - News) and Johnson & Johnson (NYSE: JNJ - News) have telaprevir for hepatitis C, while Incyte (NASDAQ: INCY - News) and Novartis (NYSE: NVS - News) are developing a drug currently known as "INCB18424" for blood cancer.
Drugs generally don't develop more market-friendly names until closer to FDA approval.
Meanwhile, J&J and Bayer's (NYSE: BYR.L - News) long-overdue blood thinner Xarelto could finally get launched this year.
Sorry, Lilly is not on the list.